These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31806196)

  • 1. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
    Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
    Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
    Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
    [No Abstract]   [Full Text] [Related]  

  • 3. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
    Sussman M; Yu JC; Menzin J
    Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
    Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
    J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
    [No Abstract]   [Full Text] [Related]  

  • 5. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
    Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
    [No Abstract]   [Full Text] [Related]  

  • 6. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
    Shafrin J; Dennen S; Pednekar P; Birch K; Bhor M; Kanter J; Neumann P
    J Manag Care Spec Pharm; 2021 May; 27(5):650-659. PubMed ID: 33779245
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of real-world evidence in ICER's scoping process and clinical evidence assessments.
    Jiao B; Veenstra DL; Lee W; Carlson JJ; Devine B
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1590-1595. PubMed ID: 33251999
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenges with Forecasting Budget Impact: A Case Study of Six ICER Reports.
    Snider JT; Sussell J; Tebeka MG; Gonzalez A; Cohen JT; Neumann P
    Value Health; 2019 Mar; 22(3):332-339. PubMed ID: 30832971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.
    Gerlach JA; Snow B; Prioli KM; Vertsman R; Patterson J; Pizzi LT
    Am Health Drug Benefits; 2020 Sep; 13(4):136-142. PubMed ID: 33343812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value Assessment in Cystic Fibrosis: ICER's Rejection of the Axioms of Fundamental Measurement.
    Langley PC
    Innov Pharm; 2020; 11(2):. PubMed ID: 34007612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
    Thokala P; Carlson JJ; Drummond M
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICER's Revised Value Assessment Framework for 2017-2019: A Critique.
    Neumann PJ; Cohen JT
    Pharmacoeconomics; 2017 Oct; 35(10):977-980. PubMed ID: 28791663
    [No Abstract]   [Full Text] [Related]  

  • 14. ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Underestimating the Value of an Intervention: The Case for Including Productivity in Value Assessments and Formulary Design.
    Karmarkar T; Graff JS; Westrich K
    J Manag Care Spec Pharm; 2020 May; 26(5):652-661. PubMed ID: 32347177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Cost-Effectiveness Assessments Require Standards for Rigor and Inclusion.
    Goss Sawhney T; Thakur N
    J Health Econ Outcomes Res; 2023; 10(1):28-30. PubMed ID: 36852154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How reliable are ICER's results published in current pharmacoeconomic literature? The controversial issue of price confidentiality.
    Russo P
    Glob Reg Health Technol Assess; 2022; 9():31-35. PubMed ID: 36628320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness Estimates.
    Breslau RM; Cohen JT; Ollendorf DA; Neumann PJ
    Pharmacoecon Open; 2022 Nov; 6(6):893-895. PubMed ID: 35871128
    [No Abstract]   [Full Text] [Related]  

  • 20. Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?
    Chapman RH; Kumar V
    J Manag Care Spec Pharm; 2019 May; 25(5):521-524. PubMed ID: 31039064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.